Clinical Trials Browser

Phase 2 × Afatinib × Head & Neck × Clear all

NCT02979977 2026-02-04

Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck

Phase 2 Completed

50 enrolled 14 charts

Squamous Cell Cancers of the Head and Neck

NCT06804850 2025-11-19

Neoadjuvant Radiotherapy Plus Targeted Therapy and Immunotherapy vs. Targeted Therapy Plus Immunotherapy in Resectable HNSCC

Phase 2 Withdrawn

Head and Neck Neoplasms

NCT05517330 2025-07-31

neoCHANCE-1

Phase 2 Completed

Head and Neck Neoplasms

NCT05516589 2025-05-22

neoCHANCE-2

Phase 2 Completed

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT03088059 2023-11-03

UPSTREAM

Phase 2 Unknown

Squamous Cell Carcinoma of Head and Neck

NCT01824823 2023-06-28

Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence

Phase 2 Terminated

3 enrolled 6 charts

Squamous Cell Carcinoma of Head and Neck

NCT03695510 2022-04-21

ALPHA

Phase 2 Completed

Head and Neck Neoplasms

NCT01415674 2022-02-02

PREDICTOR

Phase 2 Completed

Squamous Cell Carcinoma of Head and Neck

NCT01538381 2018-07-09

Neoadjuvant Afatinib Window Study in Squamous Cell Carcinoma of the Head and Neck

Phase 2 Completed

Squamous Cell Carcinoma of Head and Neck

NCT00514943 2016-07-26

BIBW 2992 (Afatinib) in Head & Neck Cancer

Phase 2 Completed

124 enrolled 31 charts

Carcinoma, Squamous Cell, Head and Neck Neoplasms